{"id":"vonoprazan-tetracycline-furazolidone-7-days","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Photosensitivity (tetracycline)"},{"rate":null,"effect":"Peripheral neuropathy (furazolidone)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker that raises gastric pH to optimize antibiotic efficacy. Tetracycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Furazolidone is a nitrofuran antimicrobial agent with activity against H. pylori. The 7-day regimen is designed to achieve high eradication rates in H. pylori infection.","oneSentence":"This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:52.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"}]},"trialDetails":[{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1487,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan+tetracycline+furazolidone 7 days","genericName":"Vonoprazan+tetracycline+furazolidone 7 days","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone). Used for Helicobacter pylori infection eradication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}